The only National Key Laboratory for Mental Health founded by the National Health and Family Planning Commission of China is located at IMH. The China National Clinical Research Center for Psychiatric and Mental Disorders was formally founded in Oct 2014. Its founding marks a major move in the state’s effort to deepen medical system reforms and implement the 12th Five-Year Plan for Medical Science Development, and takes the lead in clinical medicine and transformation research on psychiatric and mental diseases initiated by Ministry of Science and Technology and National Health and Family Planning Commission with the aim to improve medical science innovation system and clinical research capacity. The Psychology and Psychiatry of PKU has been listed in Top 1% of Essential Science Indicators (ESI).
Great achievements in scientific research have been made under the leadership and hard work of Prof. Shen Yucun and other distinguished researchers. Under the guidance of Ph.D advisors, a research team has been organized to come to the top in various fields. The Institute has conducted profound investigations in biological psychiatry, social psychiatry, child psychiatry, and clinical psychiatry, psychosomatic medicine, and neuropsychopharmacology. Over the years, the IMH has conducted numerous national-level and internationally collaborative studies and been recognized with many important research awards. Recently, there have also been great advances in nursing research.
In the field of biological psychiatry, the research team has explored the etiology and mechanisms of many common psychiatric disorders, such as schizophrenia, mood disorders, dementia, and autism, using methods of molecular genetics, neurobiochemistry, neuroimaging, neurobiology, neuroelectrophysiology, and neuropsychopharmacology. They also developed novel therapy and the guidelines for clinical treatment of psychosis. The development of extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia has enrolled the American Academy of Neurology. The genome wide association study of schizophrenia found new susceptibility genes of this disease. With supporting of the “863”, “973”, NSFC and other projects, they have published more than 100 articles in peer-review journals, which includes Nat Genet, Mol Psychiatry, Am J Psychiatry, Biol Psychiatry, Proc Natl Acad Sci USA, Cereb Cortex, NeuroImage, etc. Prof. Zhang has been listed as Top 17 in Neuroscience by Elsevier as the Most Cited Chinese Researchers.
In the field of social psychiatry, the IMH research team has invested in finding good instruments for epidemiological studies in China. The IMH research team has also guided and trained research staff from various provinces to conduct epidemiological studies using internationally recognized Composite International Diagnostic Interviews. In addition, the IMH research team has completed the Chinese psychiatric disability standard, dementia screening tools, diagnostic tools for psychiatric disorders and intervention strategies for care givers of dementia patients. The IMH has established the network for training in suicide prevention, conducted clinical trials using rTMS, carried out community-based surveys on personality disorders and internet use, and organized intervention research on PTSD. Prof. Huang’s team has just completed the China Mental Health Survey (CMHS), which is the first nationally representative community survey on mental disorders and mental health services in China. The researches have been published in Lancet, Brit J Psychiatry, Sci Rep, etc.
In the field of child psychiatry, the IMH focused on the etiology and treatment of Attention Deficit Hyperactivity Disorder (ADHD) and conduct problems. Clinical research includes studies on autism and child schizophrenia. The IMH has carried out many research projects funded by the National Health and Family Planning Commission of China, Chinese Ministry of Education, and Chinese Ministry of Science and Technology. The IMH has made great contributions with respect to the etiology, clinical evaluation, and treatment in the above areas. With supporting of the “973”, NSFC and other projects, they have published more than 90 articles in peer-review journals, which includs Mol Psychiatry, Biol Psychiatry, J Neurosci, Neuropsychopharmacol, J Am Acad Child Adolesc Psychiatry, etc.
In the field of clinical psychiatry, the IMH has been focused on psychiatric drugs, the application of therapeutic theory into practice, and clinical research on common psychiatric disorders. These studies include researches on biomarkers and the early treatment of geriatric psychiatric disorders, early detection and intervention of schizophrenia, treatment and intervention of alcohol dependence and eating disorders, psychological and behavioral studies on HIV/AIDS-related psychiatric disorders, as well as studies on mental health strategies and policies. The researches have been published in Lancet, World J Psychiatry, Mol Psychiatry, Am J Psychiatry, Hum Brain Mapp, J Alzheimers Dis, etc.
In the field of psychosomatic medicine, the IMH has been focused on the neurobiological mechanisms and clinical intervention measures of psychiatric disorders (e.g. substance addiction, sleep disorders and depression), including aberrant synaptic plasticity of depression and drug dependence, the molecular mechanisms of dynamic pathological memory, and psychological and cognitive changes of depression, drug addiction, and sleep disorders patients, as well as the pharmacological and behavioral intervention measures. Founded by the “973”, NSFC and other projects, Prof. Lu Lin’s team have originaly found the model of the memory retrieval-extinction procedure to prevent drug craving and relapse, and the neurobiological mechanisms underlying incubation of drug craving. They also reported the effect of conditioned stimulus exposure during slow wave sleep on fear memory extinction in humans. They have published more than 160 articles in peer-review journals, including Science, Nat Neurosci, Nat Commun, Biol Psychiatry, J Neurosci, Neuropsychopharma, etc. They also got the Second prize in China's State Natual Science Award, First Prize in Natual Science Award by the Ministry of Education of China, First of Chinese Medical Science and Technology Prize. They also have received the First Prize in Natual Science Award by the Ministry of Education of China, the First Prize in Chinese Medical Science and Technology Progress Prize, and the Second prize in China's State Natual Science Award. Prof. Lu has been listed as Top 5 in Medicine by Elsevier as the Most Cited Chinese Researchers.
In the field of neuropsychopharmacology, the research team majors in the basic and clinical psychopharmacology and plays a leading role in related research fields. They have built several animal models to uncover the pathophysiological mechanisms of psychiatric disorders and to find new targets for screening and developing novel antipsychotics. By recruiting patients as participants and using techniques of molecular genetics and neuroimaging, they identify biomarkers for mental diseases, follow up patients’ treatment, validate new therapies, optimize therapeutical strategies and study the predictors for individual treatment based on the clinical big-data platform. Funded by NSFC, State Project for Essential Drug Research and Development, Key Program of National Natural Science of China, and other projects, they have finished many Phase I to IV clinical trials, and published more than 60 articles in peer-review SCI journals, including Neuropsychopharm, Hum Brain Map, Psycho Med, etc, with total impact factor being 200.